Click here to close now.


News Feed Item

Diabetes - KOL Insight and Consensus Outlook Modules

NEW YORK, Feb. 13, 2014 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Diabetes – KOL Insight and Consensus Outlook Modules–-KOL-Insight-and-Consensus-Outlook-Modules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication


The medium term: battle lines are drawn
The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both established and emerging markets have seen the sector return a 5 year compound annual growth rate (CAGR) of 12% over to reach US$31.9 billion in 2012. It is estimated that 347 million people have the disease – 90% of whom are Type II diabetes sufferers – and this figure could almost double by 2030.

The big four companies in diabetes - Novo Nordisk, Sanofi, Eli Lilly and Merck – are locked in a battle of supremacy which is set to continue over the medium term. While Novo Nordisk currently leads the pack, Sanofi is close behind. With Novo Nordisk's approval of Tresiba (insulin degedec) stalled in the US over safety concerns, Sanofi latest version of Lantus U300 (insulin glargine)) could capitalise. Bristol Myers-Squibb and AstraZeneca are just two of the other players set to increase their sales significantly in this busy market place by 2017.

The diabetes market will continue on an upward trajectory, and an estimated 5 year CAGR of 11 percent will see the sector top US$54 billion – the question is which companies will have a slice to this market, and how big will it be?

What's in the pipeline?
Finding market voice for new products in diabetes depends critically on price and differentiation. Cost of treatment is already an issue and resistance can be expected from health payers if new products offer only marginal therapeutic or patient management benefits. For example, excitement about Sanofi's U300 (insulin glargine) is because it shows differentiation to Lantus with "peakless" delivery and longer duration. Eli Lilly's weekly dose dulaglutide may offer advantages over other launched and pipeline GLP-1 products such as such as GSK's Eperzan (albiglutide) and BMS/AZ/Amylin's Bydureon (exanatide) but meaningful advantages need to be shown for success in the market.

What the Future Holds: is there a Game Changer on the Horizon?
Don't expect a revolution in diabetes treatment soon. New products coming to market are essentially incremental improvements over current approaches, with better safety profiles and geared to improving patient compliance.

The real prize will be for the company that can bring a paradigm shift to the treatment of diabetes. Upsetting the status quo will require a fundamentally different approach - and some of these developments threaten the diabetes drugs manufacturers existing revenues.

Among the developments to be aware of are the threat of biosimilars, the development of an artificial pancreas 'closed loop' system, the wide implementation of which would be a doomsday development for drugs companies, and a DNA reverse vaccine for which early clinical results have shown promising results.

A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers
For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative diabetes market forecast look no further than FirstWord's Therapy Trends: Diabetes. This comprehensive FirstWord research is available in two comprehensive modules:

• The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe
• TThe Consensus Outlook: Diabetes data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts' projections


KOL Insight
Therapy Trends KOL Insight: Diabetes analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:

• KOL Insight Report — an in-depth analytical report on diabetes treatment trends
• Full report updates — issued to you after each and every significant diabetes market event
• Event Bulletins — the latest KOL views in response to each event

Key Report Features and Benefits

• Critical insights on products and market developments from leading US and European clinicians

• Complete coverage of all sub sectors - Basal, Prandial and Premixed insulins, DPP-IV inhibitors, GLP-1 agonists/analogues, SGLT-2 inhibitors, Thiazolidinediones and other non insulin anti diabetics
• Assessment of current leading diabetes products by sub sector
• Analysis of late-stage pipeline diabetes therapies by sub sector
• Competitive evaluation of leading players
• Current thinking and trends in the treatment of diabetes
• Predicted KOL treatment trends and market leaders
• Ongoing FirstWord clinical and market updates

Expert Opinion for Real World Insights
The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in diabetes in the US and Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.


• Dr Elif Oral, MD, Associate Professor of Endocrinology, University of Michigan, Ann Arbor, MI.

• Dr Sonal Singh, MD, MPH, Assistant Professor, Division of General Internal Medicines, John Hopkins University, Baltimore, MD.

• Dr Carol Wysham, MD, Clinical Associate Professor of Medicine, Division of General Internal Medicines, University of Washington School of Medicine, Washington.

• Dr Joel Zonszein, MD, Director of the Clinical Diabetes Center at the University Hospital Albert Einstein College of Medicine, a Division of Montefiori Medical Center, NY.

• Requested anonymous, Associate Professor of Medicine, Endocrinology and Metabolism, Duke University, Durham, NC.

European KOLs

• Professor Bernard Charbonnel, MD, Professor of Endocrinology and Metabolic Diseases, University of Nantes; Head of the Internal Medicine, Endocrinology and Diabetes Department, Hôtel Dieu, University Hospital of Nantes, France.
• Professor Melanie Davies, MD, Honorary Consultant, Diabetes, University Hospital Leicester, Leicestershire, UK.
• Professor Marc Donath, MD, Director, Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.
• Professor Baptist Gallwitz, MD, Professor, Professor of Medicine, Diabetes, Eberhard Karls University, University Hospital of Tuebingen, Germany.
• Professor Jens Holst, MD, Professor of Medical Physiology, Department of Biomedical Sciences; Director of the Research Cluster for Diabetes and Obesity; Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark.
• Professor Michael Nauck, MD, Head, Diabeteszentrum Bad Lauterberg, Harz, Germany.
• Professor John Wilding, MD, Head of the Department of Obesity and Endocrinology, University of Liverpool, UK.

Key Quotes from the Report
"I like Janumet. I get a much more effective medication even in one pill a day using combination therapy. Janumet has this long acting glycol, so it is long acting. In early diabetes, together with lifestyle changes, I often use a combination of DPP-IV with metformin, either once or twice a day because it doesn't cause hypoglycaemia. The patients don't need to monitor their blood sugar three, four, five times a day. They don't get admitted to the hospital with hypoglycaemia so the side effects are low. So I start treating these patients with a combination therapy, like Janumet." Dr Joel Zonszein (US)
"I think lots of people use Kombiglyze because it improves compliance so it makes sense. In the therapeutic armamentarium it's the only real once daily combination." Professor Sonal Singh (US)
"In terms of efficacy, side effects, convenience and device, Victoza is the preferred GLP-1. If I look at the new-starts, probably 60 percent of people are going for the Victoza" Dr Carol Wysham (US)
"The prevention of hypoglycaemia is a very important aim for the classical drugs and an unmet need. We should be searching for alternatives to insulin." Professor Baptist Gallwitz (EU)
"I am not too optimistic that you can improve DPP-IV inhibitors to be more efficacious. You may well be able to improve GLP-1 agonists to have more efficacious drugs that have less side effects based on the variety within the class that we have seen until now. I think that the pharmaceutical industry as a whole is a little bit running out of ideas, so we really need to identify good targets." Professor Michael Nauck (EU)
"I think if someone came up with a reasonably well-tolerated drug that helped you lose weight [and] that you only had to take once a month or once a year? Everyone would be on that. US Key Opinion Leader
"Our local insurance company have taken all of what they consider tier 3 drugs, and they include all the GLP-1 agents including the DPP-IV inhibitors, and just put them on a 50-percent co-pay. Fifty percent of a lot of money is still a lot of money." Dr Carol Wysham (US)

KOL Insights -- Key Topics

• Current diabetes marketplace

• Epidemiology

• Aetiology

• Diagnosis

• Current treatment landscape

• Reimbursement of key diabetes brands

• Current marketed therapies

• Pipeline therapies

• Unmet needs

• Current treatment algorithm

• Future treatment algorithm

• Future developments in Diabetes

Consensus Outlook
Use this detailed report and powerful interactive Excel spreadsheet to compare and contrast companies and products now and in the future. Therapy Trends Consensus Outlook: Diabetes includes the following comprehensive resources:

• An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
• An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
• Timely event-driven market forecast report and data analysis updates over 12 months

Report features:

• Historical diabetes sales from 2007–2012
• Forecast diabetes sales from 2013-2017
• Key competitors and drug developers
• Current and late-stage pipeline drugs
• Future event mapping to forecast data points
• Expected impacting factors on global forecasts

Use Consensus Outlook to:

• •Chart predicted market growth and product sales
• Map your own market parameters
• Tailor your strategic and investment focus
• Assess your current and future sales resources
• Set proactive launches and branding strategies

Analysts compared:

• Barclays Capital
• Credit Suisse
• Deutsche Bank
• Goldman & Sachs
• International Strategy & Investment
• Jefferies
• JP Morgan
• Merrill Lynch
• Morgan & Stanley
• Societe Generale
• Stifel Nicolaus
•Wells Fargo


Content Highlights and Products Covered:

• Research Methodology
• Diabetes Marketplace
• Key Diabetes Developers
• Diabetes Class Dynamics
• Lantus (insulin glargine; Sanofi) forecast
• Levemir (insulin detemir; Novo Nordisk) forecast
• Tresiba (insulin degludec; Novo Nordisk) forecast
• Ryzodeg (degludecPlus; Novo Nordisk) forecast
• NovoRapid/NovoLog (insulin aspart; Novo Nordisk) forecast
• Humalog (insulin lispro; Eli Lilly) forecast
• Apidra (insulin glulisine; Sanofi) forecast
• NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) forecast
• Januvia franchise (sitagliptin; Merck & Co) forecast
• Galvus franchise (vildagliptin; Novartis) forecast
• Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) forecast
• Nesina franchise (alogliptin; Takeda) forecast
• Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) forecast
• Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast
• Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast
• Victoza (liraglutide; Novo Nordisk) forecast
• Lyxumia (lixisenatide; Sanofi) forecast
• Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) forecast
• Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) forecast
• Actos (pioglitazone; Takeda) forecast
• U300 (insulin glargine; Sanofi) forecast
• LY2605541 (insulin peglispro; Eli Lilly) forecast
• LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) forecast
• IDeglira (liraglutide + insulin degludec; Novo Nordisk) forecast
• Afrezza (Technosphere Insulin; MannKind Corporation) forecast
• FIAsp (insulin aspart; Novo Nordisk) forecast
• Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast
• LY2189265 (dulaglutide; Eli Lilly) forecast
• BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) forecast

Contents Consensus Outlook
1.FirstWord Analysis Highlights
2.Research Methodology
3.Diabetes Marketplace
4.Key Diabetes Developers
5.Diabetes Class Dynamics
6.Lantus (insulin glargine; Sanofi) forecast
7.Levemir (insulin detemir; Novo Nordisk) forecast
8.Tresiba (insulin degludec; Novo Nordisk) forecast
9.Ryzodeg (degludecPlus; Novo Nordisk) forecast
10.NovoRapid/NovoLog (insulin aspart; Novo Nordisk) forecast
11.Humalog (insulin lispro; Eli Lilly) forecast
12.Apidra (insulin glulisine; Sanofi) forecast
13.NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) forecast
14.Januvia franchise (sitagliptin; Merck & Co) forecast
15.Galvus franchise (vildagliptin; Novartis) forecast
16.Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) forecast
17.Nesina franchise (alogliptin; Takeda) forecast
18.Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) forecast
19.Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast
20.Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast
21.Victoza (liraglutide; Novo Nordisk) forecast
22.Lyxumia (lixisenatide; Sanofi) forecast
23.Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) forecast
24.Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) forecast
25.Actos (pioglitazone; Takeda) forecast
26.U300 (insulin glargine; Sanofi) forecast
27.LY2605541 (insulin peglispro; Eli Lilly) forecast
28.LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) forecast
29.IDeglira (liraglutide + insulin degludec; Novo Nordisk) forecast
30.Afrezza (Technosphere Insulin; MannKind Corporation) forecast
31.FIAsp (insulin aspart; Novo Nordisk) forecast
32.Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast
33.LY2189265 (dulaglutide; Eli Lilly) forecast
34.BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) forecast

KOL Insights
4.Current diabetes marketplace
5.Diabetes overview
5.1.Diabetes definition
5.2.Diabetes segmentation
5.5.Risk factors
5.7.Complications of diabetes
5.9.Diabetes treatment
5.10.Current treatment landscape
5.11.Reimbursement of key diabetes brands
6.Current marketed therapies
6.1.Basal insulins
6.2.Prandial insulins
6.3.Premixed insulins
6.4.Dipeptidyl Peptidase-IV (DPP-IV) inhibitors
6.5.Glucagon-like peptide-1 (GLP-1) agonists/analogues
6.6.Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
6.7.Thiazolidinediones (TZD)
6.8.Other non-insulin anti-diabetics
7.Pipeline therapies
7.1.Pipeline basal insulins
7.2.Pipeline prandial insulins
7.3.Pipeline dipeptidyl peptidase-IV (DPP-IV) inhibitors
7.4.Pipeline glucagon-like peptide-1 (GLP-1) agonists/analogues
7.5.Pipeline sodium-glucose co-transporter 2 (SGLT-2) inhibitors
7.6.Other pipeline non-insulin anti-diabetics
8.Treatment focus
8.1.Unmet needs in type 1 diabetes
8.2.Unmet needs in type 2 diabetes
8.3.Current treatment algorithm- Type2 diabetes
8.4.Future treatment algorithm
9.Future developments in Diabetes
9.1.Biosimilar insulin commercial threat limited
9.2.Continuous glucose monitoring and closed loop systems
9.3.Transplantation or regeneration of beta-cells
9.4.Targeting immune response and inflammation
10.1.KOL biographies

To order this report: Diabetes – KOL Insight and Consensus Outlook Modules–-KOL-Insight-and-Consensus-Outlook-Modules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001


SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, explored the IoT cloud-based platform technologies driving t...
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
As organizations shift towards IT-as-a-service models, the need for managing & protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection & E-Discovery of your data - whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise.
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, presented how organizations can use eFolder Cloudfinder to automate backups of cloud application data. He also demonstrated how easy it is to search and restore cloud application data using Cloudfinder.
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Su...
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
The Internet of Everything is re-shaping technology trends–moving away from “request/response” architecture to an “always-on” Streaming Web where data is in constant motion and secure, reliable communication is an absolute necessity. As more and more THINGS go online, the challenges that developers will need to address will only increase exponentially. In his session at @ThingsExpo, Todd Greene, Founder & CEO of PubNub, exploreed the current state of IoT connectivity and review key trends and t...
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessi...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...